Cymbalta for generalised anxiety disorder

The licence for Cymbalta (duloxetine) has been extended to include use in the treatment of generalised anxiety disorder (GAD).

The recommended starting dose in patients with GAD is 30mg once daily, taken with or without food. In patients with insufficient response the dose should be increased to 60mg, the usual maintenance dose in most patients.

In patients with co-morbid major depressive episodes, the starting and maintenance dose is 60mg once daily.

Doses up to 120mg daily have been shown to be efficacious and have been evaluated for safety in clinical trials; escalation up to 90mg or 120mg may be considered for patients with insufficient response to 60mg.

After consolidation of the response, continue treatment for several months to avoid relapse.


Further information: Lilly
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...